You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Observed mortality rate according to risk class CURB65-A (based on ProADM and CURB65)

From: Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: Derivation of a clinical algorithm

  All LRTI patients (1359) CAP patients (n = 925)
  n Adverse events (95%CI) Mortality (95%CI) n Adverse events (95%CI) Mortality (95%CI)
CURB65 risk classes       
CURB65 0-1 659 6.83 (4.9-8.76) 0.76 (0.09-1.42) 427 8.67 (5.99-11.34) 0.94 (0.02-1.85)
CURB65 2 434 14.75 (11.4-18.1) 8.06 (5.49-10.64) 296 15.54 (11.39-19.69) 8.45 (5.26-11.63)
CURB65 3-5 266 22.93 (17.85-28.02) 10.15 (6.5-13.8) 202 25.25 (19.21-31.29) 10.4 (6.15-14.64)
ProADM categories       
ProADM <0.75 nmol/l 353 4.25 (2.13-6.36) 0.85 (-0.11-1.81) 194 5.67 (2.39-8.95) 1.55 (-0.21-3.3)
ProADM 0.75 - 1.5 nmol/l 588 9.01 (6.69-11.34) 2.72 (1.4-4.04) 400 10 (7.05-12.95) 2.75 (1.14-4.36)
ProADM >1.5 nmol/l 418 24.4 (20.27-28.54) 11.48 (8.41-14.55) 331 25.08 (20.38-29.77) 10.88 (7.5-14.25)
CURB65-A       
Risk class 1 306 3.92 (1.73-6.11) 0.65 (0.25-1.56) 167 5.39 (1.93-8.85) 1.2 (0.47-2.86)
Risk class 2 534 8.61 (6.23-11) 2.62 (1.26-3.98) 360 9.72 (6.65-12.8) 2.78 (1.07-4.48)
Risk class 3 519 21.58 (18.03-25.13) 9.83 (7.26-12.4) 398 22.61 (18.49-26.74) 9.55 (6.65-12.45)
Total 1359 12.51 (10.75-14.27) 4.93 (3.78-6.08) 925 14.49 (12.21-16.76) 5.41 (3.95-6.87)